News

Prescient Medicine and Erasmus MC Partner to Study Opioid Addiction Risk

CARLSBAD, Calif. and ROTTERDAM, Netherlands, Dec. 10, 2019 /PRNewswire/ -- Prescient Medicine Holdings, Inc. and the Department of Clinical Chemistry at Erasmus MC (CC-EMC), Rotterdam today announced a partnership for CC-EMC to study opioid addiction risk…

Read More

Prescient Medicine Hires New Chief Commercial Officer

CARLSBAD, Calif., Nov. 12, 2019 /PRNewswire/ -- Prescient Medicine Holdings, Inc. recently announced Tony Grover as its new Chief Commercial Officer based in Carlsbad, California. In this position, Grover will build and execute go-to market…

Read More

FDA Grants Breakthrough Device Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer

CARLSBAD, California, September 4th, 2019 -- Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has…

Read More

Gut microbiome identifies risk for colorectal polyps

Objective To characterise the gut microbiome in subjects with and without polyps and evaluate the potential of the microbiome as a non-invasive biomarker to screen for risk of colorectal cancer (CRC).…

Read More

Prescient Medicine Holdings Inc. Acquires AutoGenomics Inc.

Hummelstown, Pennsylvania, April 23, 2019 - Prescient Medicine Holdings Inc. announced today it has acquired AutoGenomics Inc., a privately-held U.S. molecular diagnostics company, which has developed and commercialized the INFINITI®…

Read More